Published in
Elsevier, Clinical Colorectal Cancer, 4(17), p. 313-319, 2018
DOI: 10.1016/j.clcc.2018.06.002
Links
Tools
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA- wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study
Journal article published in 2018 by
Jeremy D. Shapiro,
Subotheni Thavaneswaran,
Craig R. Underhill 
,
Kristy P. Robledo,
Christos S. Karapetis,
Fiona L. Day,
Louise M. Nott,
Michael Jefford ,
Lorraine A. Chantrill,
Nick Pavlakis,
Niall C. Tebbutt,
Timothy J. Price ,
Mustafa Khasraw,
Guy A. Van Hazel,
Paul M. Waring
and other authors.
,
Kristy P. Robledo,
Christos S. Karapetis,
Fiona L. Day,
Louise M. Nott,
Michael Jefford ,
Lorraine A. Chantrill,
Nick Pavlakis,
Niall C. Tebbutt,
Timothy J. Price ,
Mustafa Khasraw,
Guy A. Van Hazel,
Paul M. Waring
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 